Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: Thromb Res. 2019 Feb 13;177:59–69. doi: 10.1016/j.thromres.2019.01.017

Fig. 3.

Fig. 3.

Prasugrel is more potent inhibitor than Clopidogrel of platelet PAR1-mediated platelet aggregation. Inhibition of platelet aggregation was compared at early 2 min (A) and final 15 min (B) time point for platelets stimulated with 5 μΜ SFLLRN. Data are reported as mean ± SE (n = 12). Prasugrel (●), Clopidogrel (○).